Abstracts tagged "Pediatric rheumatology"

Abstract Number: 011 • 2023 Pediatric Rheumatology Symposium
The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Emily Beil¹, Eyal Muscal², Danielle Guffey², Marietta Deguzman¹ and Erin Peckham-Gregory², ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Differences in prevalence rates of childhood-onset SLE (cSLE) among different racial/ethnic groups have been well described. Yet, the role of social determinants of health…
Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium
Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort
Sara Patrizi¹, Megha Tandel², Derek Boothroyd² and Joyce Hsu¹, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
Abstract Number: 084 • 2023 Pediatric Rheumatology Symposium
Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic
Kristiana Nasto¹, David McDonald¹, Kyla Fergason¹, Mary Robichaux¹, Bernard Danna¹, Monique Maher¹, Alexander Alexander¹, Danielle Guffey¹, Miriah Gillispie-Taylor² and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Transition of adolescents with chronic healthcare needs to adult care may result in poor outcomes. We have developed a program to improve the transition…
Abstract Number: 125 • 2023 Pediatric Rheumatology Symposium
Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Catherine Lavallee¹, Sabrina Gmuca² and Melissa Lerman², ¹Virginia Tech Carilion School of Medicine, ROANOKE, VA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Non-infectious pediatric uveitis is a vision threatening disease whose treatment involves both ophthalmologists and rheumatologists.In other diseases necessitating multidisciplinary care, coordinated care clinics have…
Abstract Number: 015 • 2023 Pediatric Rheumatology Symposium
Epigenetically-Distinct B Cell Profiles Pre- and Post-Induction Therapy in Pediatric Lupus
Joyce Hui-Yuen¹, Kaiyu Jiang², Susan malkiel³, Betty Diamond⁴ and James Jarvis⁵, ¹Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ²University at Buffalo, Buffalo, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) may be triggered by gene-environment interactions. Data are scarce on how epigenetic variance contributes to disease risk in pediatric SLE…
Abstract Number: 052 • 2023 Pediatric Rheumatology Symposium
Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients
Yoel Levinsky¹, Rotem Tal², Liora Harel², Shoval Shoham³, Sabreen Abu Ahmad⁴, Yonatan Butbul Aviel⁵, Gil Amarilyo² and Mor Broide³, ¹Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ²Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Ruth Rappaport Children's Hospital, Rambam Health Care, Haifa, Israel, ⁵Rambam Medical center, Haifa, Israel
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children; by definition, episodes occur every…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 128 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Paul Tsoukas¹, Hua Lu², Marla Mendes de Aquino², Michael Ombrello³, Lisa Strug² and Rae Yeung⁴, ¹The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a novel clinical entity presenting following SARS CoV2 infection. This study describes a subgroup of MIS-C patients…
Abstract Number: 0034 • ACR Convergence 2022
Association of Anti-Tropomyosin Alpha-4 Autoantibodies with Cutaneous Manifestations in Juvenile Dermatomyositis
Rie Karasawa¹, James Jarvis², Toshiko Sato¹, Megumi Tanaka¹, Terrance P O'Hanlon³, Payam Noroozi-Farhadi⁴, Willy A. Flegel⁵, Kazuo Yudoh¹ and Lisa G Rider³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, ³Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH, Garrett Park, MD
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory autoimmune diseases in children. JDM is characterized by…
Abstract Number: 0515 • ACR Convergence 2022
Juvenile Systemic Sclerosis Treatment Practices in an International Cohort and Comparison to Recent SHARE Consensus Guidelines
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Ana Paula Sakamoto⁷, Brian Feldman⁸, Jordi Anton⁹, FLAVIO SZTAJNBOK¹⁰, Valda Stanevica¹¹, Simone Appenzeller¹², Tadey Avcin¹³, Sindu Johnson¹⁴, Raju Khubchandani¹⁵, Mikhail Kostik¹⁶, Edoardo Marrani¹⁷, Walter Alberto Sifuentes-Giraldo¹⁸, Dana Nemcova¹⁹, Maria José Santos²⁰, Dieneke Schonenberg-Meinema²¹, Cristina Battagliotti²², Lillemor Berntson²³, Blanca Bica²⁴, Jürgen Brunner²⁴, Rolando Cimaz²⁵, Despina Eleftheriou²⁶, Liora Harel²⁷, Gerd Horneff²⁸, Mahesh Janarthanan²⁹, Tilmann Kallinich³⁰, Thomas Lehman³¹, Farzana Nuruzzaman³², Anjali Patwardhan³³, Vanessa Smith³⁴ and Nicola Helmus³⁵, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ⁴Cerrahpaşa Medical School, Istanbul University, Istanbul, Turkey, ⁵Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ⁶Universidad Federal São Paulo, São Paulo, Brazil, ⁷Federal University of Sao Paulo (UNIFESP), São Paulo, Brazil, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁹Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹⁰UFRJ/UERJ, São Paulo, Brazil, ¹¹Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹²Unicamp, Campinas, São Paulo, Brazil, ¹³University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁴University of Toronto, Toronto, ON, Canada, ¹⁵SRCC Children's Hospital, Mumbai, India, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁷University of Florence, Firenze, Italy, ¹⁸Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁹Charles University, Prague, Czech Republic, ²⁰Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ²¹Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²²Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²³Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²⁴UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ²⁵University of Milano, Milano, Italy, ²⁶Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ²⁷Schneider Children's Medical center, Tel Aviv University, Nettnja, Israel, ²⁸Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ³⁰Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ³¹Hospital for Special Surgery, New York, NY, ³²Stony Brook Children's Hospital, East Setauket, NY, ³³University of Missouri, Columbia, MO, ³⁴Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ³⁵Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently no medications are licensed for the treatment…
Abstract Number: 0866 • ACR Convergence 2022
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
Sheila Angeles-Han¹, Grant Schulert¹, Megan Quinlan-Waters¹, Alexandra Duell¹, Jennifer Huggins¹, Tiffany Nguyen², Cameron Sapp², Sumit Sharma³, Sunil Srivastava⁴ and Arjun Sood², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cole Eye Institute, Cleveland Clinic, Cleveland, OH, ⁴Cole Eye Institute, Cleveland Clinic, Cincinnati, OH
Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
Abstract Number: 1301 • ACR Convergence 2022
Reliable Transition Policy Distribution and Transition Readiness Assessment Questionnaire Completion Using a Digital Intervention in a Pediatric Rheumatology Clinic
Emily Smitherman¹, Livie Huie¹, John Bridges², Randy Cron¹, Victoria Gennaro³, Kim Jerkins¹, Julie Mauldin¹, Linda McAllister⁴, Annelle Reed³, Daniel Reiff¹, Erica Reynolds³, Isabella Sanchez³, Carolyn Smith³, Matthew Stoll¹, Tana Webb¹, Peter Weiser¹, JoAnne Zech¹ and Melissa Mannion¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ³Children's of Alabama, Birmingham, AL, ⁴Children's of Alabama, Trussville, AL
Background/Purpose: The process of transition from pediatric- to adult-based care should be well-timed, coordinated, and planned to educate and encourage the adolescent towards an adult…
Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Jordan Roberts¹, Mindy Lo¹, Rebecca Sadun², Emily Smitherman³, Scott Wenderfer⁴ and Mary Beth F. Son¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Duke University, Durham, NC, ³University of Alabama at Birmingham, Birmingham, AL, ⁴British Columbia Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…
Abstract Number: 1927 • ACR Convergence 2022
Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults
Rebecca Overbury¹, Devin Eddington², Katherine Sward², John Bohnsack¹, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City
Background/Purpose: The Adult Center for Childhood Onset Rheumatic Disease (ACCORD) is a clinical and research center for the health care transition (HCT) of adolescent and…
Abstract Number: 1949 • ACR Convergence 2022
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
amit ziv¹, Merav Heshin-Bekenstein², Ruby Haviv³, Shaye Kivity⁴, doron netzer⁵, shlomit yaron⁵, yoav schur⁵, tsipi egert⁶, yona egert⁶, yaron sela⁷, Philip Hashkes⁸ and Yosef Uziel⁹, ¹Meir Hospital, Kfar Saba, Israel, ²Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ³Meir Medical Center, Ra'Anana, Israel, ⁴Meir Medical Center, Kefar Saba, Israel, ⁵Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel, ⁶Inbar, NPO, Ramat Gan, Israel, ⁷The Research Center for Internet Psychology, School of Communications, Reichman University, Herzliya, Israel, ⁸Shaare Zedek Medical Center, Jerusalem, Israel, ⁹Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Background/Purpose: Effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory rheumatic diseases (IRD) is unknown. Several studies suggested attenuated immunogenicity in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].